Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2006 | Original Article

Comparative value of brain perfusion SPECT and [¹²³I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease

Authors: Haruo Hanyu, Soichiro Shimizu, Kentaro Hirao, Hidekazu Kanetaka, Toshihiko Iwamoto, Taishiro Chikamori, Yasuhiro Usui, Akira Yamashina, Kiyoshi Koizumi, Kimihiko Abe

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2006

Abstract

Purpose

Both decreased occipital perfusion on brain single-photon emission computed tomography (SPECT) and reduction in cardiac ¹²³I-metaiodobenzylguanidine (MIBG) uptake are characteristic features of dementia with Lewy bodies (DLB), and potentially support the clinical diagnosis of DLB. The aim of this study was to compare the diagnostic value of these two methods for differentiation of DLB from Alzheimer’s disease (AD).

Methods

The study population comprised 19 patients with probable DLB and 39 patients with probable AD who underwent both SPECT with N-isopropyl-p-[¹²³I]iodoamphetamine and MIBG myocardial scintigraphy. Objective and quantitative measurement of perfusion in the medial occipital lobe, including the cuneus and lingual gyrus, was performed by the use of three-dimensional stereotactic surface projections.

Results

Medial occipital perfusion was significantly decreased in the DLB group compared with the AD group. The mean heart/mediastinum ratios of MIBG uptake were significantly lower in the DLB group than in the AD group. Although SPECT failed to demonstrate significant hypoperfusion in the medial occipital lobe in five patients with DLB, marked reduction of MIBG uptake was found in all patients with DLB. Receiver operating characteristic analysis revealed that MIBG myocardial scintigraphy enabled more accurate discrimination between DLB and AD than was possible with perfusion SPECT.

Conclusion

MIBG myocardial scintigraphy may improve the sensitivity in the detection of DLB. In particular, this method may provide a powerful differential diagnostic tool when it is difficult to distinguish cases of DLB from AD using brain perfusion SPECT.

McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28CrossRefPubMed

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24PubMed

Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462–6PubMed

Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998;51:125–30PubMed

Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247–56CrossRefPubMed

Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–65CrossRefPubMed

Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999;53:413–6PubMed

Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–9PubMed

Pasquier J, Michel B, Brenot-Rossi I, Hassan-Sebbag N, Sauvan R, Gastaut JL. Value of ^99mTc-ECD SPET for diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2002;29:1342–8CrossRefPubMed

10.

Donnemiller E, Heilmann J, Wenning G, Berger W, Decristoforo C, Moncayo R, et al. Brain perfusion scintigraphy with ^99mTc-HMPAO or ^99mTc-ECD and ¹²³I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320–5PubMed

11.

Colloby SJ, Fenwick JD, Williams D, Paling SM, Lobotesis K, Ballard C, et al. A comparison of ^99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002;29:615–22CrossRefPubMed

12.

Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dement Geriatr Cogn Disord 2005;20:25–30CrossRefPubMed

13.

Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H.¹²³I-metaiodobenzyl guanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:189–94PubMed

14.

Taki J, Nakajima K, Hwang E-H, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566–73CrossRefPubMed

15.

Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [¹²³I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53:1020–5PubMed

16.

Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc J-L, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 2003;18:890–7CrossRefPubMed

17.

Yoshita M, Taki J, Yamada M. A clinical role for [¹²³I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583–8CrossRefPubMed

18.

Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M, et al. Cardiac ¹²³I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:781–3CrossRefPubMed

19.

Oide T, Tokuda T, Momose M, Oguchi K, Nakamura A, Ohara S, et al. Usefulness of [¹²³I]metaiodobenzylguanidine ([¹²³I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med 2003;42:686–90PubMed

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–44PubMed

21.

Solanski KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513–21PubMed

22.

Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98CrossRefPubMed

23.

Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48PubMed

24.

Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain. New York: Thieme; 1998

25.

Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528–37PubMed

26.

Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003;17:289–95PubMed

27.

Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann Nucl Med 2003;17:309–13PubMed

28.

Ballard C, Shaw F, McKeith I, Kenny RA. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 1998;51:1760–2PubMed

29.

Algotsson A, Viitanen M, Winblad B, Solders G. Autonomic dysfunction in Alzheimer’s disease. Acta Neurol Scand 1995;91:14–8PubMed

30.

Wang S-J, Liao K-K, Fuh J-L, Lin K-N, Wu Z-A, Liu C-Y, et al. Cardiovascular autonomic functions in Alzheimer’s disease. Age Ageing 1994;23:400–4PubMed

31.

Szili-Torok T, Kalman J, Paprika D, Dibo G, Rozsa Z, Rudas L. Depressed baroreflex sensitivity in patients with Alzheimer’s and Parkinson’s disease. Neurobiol Aging 2001;22:435–8CrossRefPubMed

32.

Ishii T. Distribution of Alzheimer’s neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol 1966;6:181–7CrossRefPubMed

33.

McDuff T, Sumi SM. Subcortical degeneration in Alzheimer’s disease. Neurology 1985;35:123–6PubMed

34.

Yates CM, Ritchie IM, Simpson J. Noradrenalin in Alzheimer-type dementia and Down’s syndrome. Lancet 1981;ii:39–40CrossRef

35.

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:249–51CrossRefPubMed

36.

Taki J, Yoshita M, Yamada M, Tonami N. Significance of ¹²³I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004;18:453–61PubMed

37.

Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol 2002;15:200–9PubMed

38.

Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies. A volumetric MRI study. Neurology 1998;51:357–62PubMed

39.

Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000;54:1304–9PubMed

40.

Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618–30CrossRefPubMed

41.

Hanyu H, Shimizu S, Tanaka Y, Kanetaka H, Iwamoto T, Abe K. Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer’s disease. Neurosci Lett 2005;380:166–9CrossRefPubMed

42.

Waker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134–40CrossRefPubMed

43.

O’Brien JT, Colloby S, Fenwick J, Williams D, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25CrossRefPubMed

44.

Colloby SJ, O’Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to¹²³I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson’s disease. Neuroimage 2004;23:956–66CrossRefPubMed

45.

Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practical parameter: diagnosis of dementia (an evidence-based review), report of the quality standards subcommittee of the American Academy of neurology. Neurology 2001;56:1143–53PubMed

46.

McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050–8PubMed

Title: Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease
Authors: Haruo Hanyu
Soichiro Shimizu
Kentaro Hirao
Hidekazu Kanetaka
Toshihiko Iwamoto
Taishiro Chikamori
Yasuhiro Usui
Akira Yamashina
Kiyoshi Koizumi
Kimihiko Abe
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1921-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparative value of brain perfusion SPECT and [¹²³I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2006

March 2006

Trigemino-cardiac reflex during skull base surgery: a new entity of ischaemic preconditioning? The potential role of imaging

Increased rate of dicentric chromosomes in French Polynesian thyroid cancer patients?

Reply

False-positive FDG-PET scan due to brown tumours

From the heart to the brain via cardiac MIBG imaging